Tumor Genomic Profiling Reports from Different Vendors: A Comparison with Respect to Clinical Action Ability of the Provided Data

Abstract

Background: Next generation sequencing (NGS) of selected genes is an expanding field of solid tumor characterization. Multiple vendors offer this service, but panel design and policies on interpretive reporting are variable. This study compared reports from selected vendors, with emphasis on clinical Action ability reporting.